Table 3.

IRS scores from immunohistochemistry analyses before and after erlotinib treatment (n = 31)

AntigenNo. positive samples (%)IRS results before erlotinib treatment
IRS results after erlotinib treatment
Change in IRS after erlotinib treatment (R M ANOVA)
Mean ± SDRangeMean ± SDRangeP
EGFR31 (100)9.87 ± 3.213-129.90 ± 3.343-12ns
Phosphorylated EGFR27 (87)4.25 ± 3.250-123.48 ± 2.930-12ns
Phosphorylated Tyr29 (94)5.74 ± 3.780-123.80 ± 3.230-120.034
Phosphorylated Akt25 (81)2.87 ± 2.880-122.48 ± 2.090-8ns
STAT330 (97)5.73 ± 3.230-125.83 ± 3.800-12ns
STAT5b29 (94)5.03 ± 3.740-124.87 ± 3.740-12ns
Phosphorylated erk 1/223 (74)2.48 ± 2.690-91.12 ± 1.520-60.017
p21waf29 (94)3.25 ± 2.710-123.74 ± 2.951-12ns
p2729 (94)2.38 ± 1.560-62.93 ± 2.440-12ns
  • Abbreviations: R M ANOVA, repeated measures ANOVA; ns, not significant.